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Outcomes Associated With Familial Versus Nonfamilial Atrial
Fibrillation: A Matched Nationwide Cohort Study
Anna Gundlund, MD; Jonas Bjerring Olesen, MD, PhD; Laila Staerk, MD; Christina Lee, MB; Jonathan P. Piccini, MD, MHS, FHRS;
Eric D. Peterson, MD, MPH; Lars Køber, MD, DMSc; Christian Torp-Pedersen, MD, DMSc; Gunnar H. Gislason, MD, PhD;
Emil Loldrup Fosbøl, MD, PhD
Background-—We examined all-cause mortality and long-term thromboembolic risk (ischemic stroke, transient ischemic attack,
systemic thromboembolism) in patients with and without familial atrial fibrillation (AF).
Methods and Results-—Using Danish nationwide registry data, we identified all patients diagnosed with AF (1995–2012) and
divided them into those with familial AF (having a first-degree family member with a prior AF admission) and those with nonfamilial
AF. We paired those with and without familial AF according to age, year of AF diagnosis, and sex in a 1:1 match. Using cumulative
incidence and multivariable Cox models, we examined the risk of long-term outcomes. We identified 8658 AF patients (4329
matched pairs) with and without familial AF. The median age was 50 years (interquartile range 43–54 years), and 21.4% were
women. Compared with nonfamilial AF patients, those with familial AF had slightly less comorbid illness but similar overall
CHA2DS2-VASc score (P=0.155). Median follow-up was 3.4 years (interquartile range 1.5–6.5 years). Patients with familial AF had
risk of death and thromboembolism similar to those with nonfamilial AF (adjusted hazard ratio 0.91 [95% CI 0.79–1.04] for death
and 0.90 [95% CI 0.71–1.14] for thromboembolism).
Conclusions-—Although family history of AF is associated with increased likelihood for development of AF, once AF developed,
long-term risks of death and thromboembolic complications were similar in familial and nonfamilial AF patients. ( J Am Heart
Assoc. 2016;5:e003836 doi: 10.1161/JAHA.116.003836)
Key Words: atrial flutter • complication • family history • genetics
A complete understanding of atrial fibrillation (AF) and itspathophysiology is lacking. Since 1997, several single-
point genetic loci have been correlated to AF,1–5 suggesting a
genetic etiology for AF, at least in some cases. Three specific
genomic regions associated with AF were identified recently
through genomewide association studies of chromosome
4q25, 16q22, and 1q21.6–9 In addition, recent studies showed
that AF aggregates in families.10–15 These studies indicated
that family history of AF may be considered an important risk
factor for AF. Furthermore, patients with first-degree relatives
diagnosed with AF (familial AF) have been shown to be
younger and to have less comorbidity than AF patients
without a family history of AF.10–12,16,17 Nevertheless, no
long-term outcome data exist for familial AF.
Death and thromboembolism are important long-term
complications of AF; for example, AF is associated with a 5-
fold increased risk of stroke.18 Antithrombotic treatment is
used to prevent thromboembolic complications in these
patients, and the treatment strategy is independent of family
history of AF. Information regarding potential differences in
these outcomes among familial and nonfamilial AF patients is
needed to help clarify whether these 2 patient groups would
benefit from different treatment strategies.
The aim of this study was to examine all-cause mortality
and thromboembolic risk (stroke, transient ischemic attack,
systemic thromboembolism) in AF patients with familial AF
compared with patients with nonfamilial AF.
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Methods
Data Sources
All residents of Denmark are included in a set of nationwide
administrative registries. The Danish Civil Registration System
(since 1968) holds complete information about sex and date
of birth.19 It includes complete information about parents (at
least the mother) from 1930 onward and about siblings from
1942 onward. All in- and outpatient hospital contacts (not
including general practitioner visits) in Denmark are regis-
tered in the Danish National Patient Registry (since 1978), in
which all given diagnoses at discharge are registered in terms
of International Classification of Diseases (ICD) codes. In
Denmark, the eighth revision (ICD-8) was used until 1994, and
the 10th revision (ICD-10) was used thereafter.20 All
dispensed prescriptions have been registered since 1995 at
an individual level in the Danish National Registry of Medicinal
Statistics. The registry is complete because all Danish
pharmacies are mandated by law to register and report all
filled prescriptions.21 It is also mandatory under Danish law
for physicians to complete a death certificate for any death
occurring in Denmark. This certificate is registered in the
Danish Register of Causes of Death, which holds information
about the cause of death.22 For the purpose of this study, we
linked data from these 4 registries using personal identifica-
tion numbers that all residents of Denmark are given at birth
or immigration.
Study Patients
We included all Danish residents born after January 1, 1895,
who were diagnosed with AF in the period from 1995 to 2012.
Adopted and stillborn persons were excluded. First, we
identified all AF patients who had a proband diagnosed with
AF and defined these patients as the familial AF patients that
constituted the cases in the study. A proband was defined as
a first-degree family member (parent or sibling) who was
diagnosed with AF in the period 1978 to 2012 and prior to the
date of the AF diagnosis of the case. Siblings were defined as
2 persons having the same mother. Second, we identified all
AF patients without a proband with AF (controls). We excluded
all controls without registration of both parents. We matched
the cases and the controls with a 1:1 match for age at AF
diagnosis, year of AF diagnosis, and sex, using the Greedy
Match method (http://www.mayo.edu/research/docu-
ments/gmatchsas/doc-10027248). Patient selection is
shown in Figure 1.
The diagnosis of AF was obtained from the Danish National
Patient Registry and was defined as a combined diagnosis of
AF and atrial flutter (ICD-8 codes 4279 and 42793 and ICD-10
code I48). This diagnosis was validated in a Danish
registry-based study with a positive predictive value of
92.6% (95% CI 88.8–95.2%) and no significant difference
between sexes (positive predictive value 2.8%, 95% CI 3.4%
to 9.0%).23
Outcomes
Information about time of death was obtained from the Danish
Civil Registration System. A thromboembolic event was
defined as stroke (ICD-10 codes I63 and I64), transient
ischemic attack (ICD-10 codes G45.8 and G45.9), or systemic
embolism (ICD-10 code I74), and data were obtained from the
Danish National Patient Registry and the Danish Register of
Figure 1. Patient selection. AF indicates atrial fibrillation.
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Causes of Death. Patients were followed from the date of their
AF diagnosis until the time of event, emigration, death, or the
end of study period (December 31, 2012), whichever came
first. The accumulation of risk-time began at the date of AF
diagnosis.
Statistics
Baseline characteristics including patient demographics,
comorbidities, use of pharmacotherapy (in a period from
3 months before the diagnosis of AF until 7 days after
discharge), and CHA2DS2-VASc score are presented by family
history of AF. Characteristics were compared using the
Kruskal–Wallis test for continuous variables and the chi-
square test for categorical variables. The CHA2DS2-VASc
score was calculated, as described previously.24 Using the
Kaplan–Meier estimator, we calculated the survival probability
according to family history of AF. The cumulative incidence of
a thromboembolic outcome in the 2 groups of patients was
assessed using the Aalen-Johansen estimator (incorporating
the competing risk of death). We tested for differences
between the 2 groups using the Fine and Gray test. We
estimated the association of a family history of AF with each
outcome using multivariable adjusted Cox proportional haz-
ards models. We adjusted for age at AF diagnosis, year of AF
diagnosis, sex, comorbidities (including dementia; AIDS;
stroke, transient ischemic attack, or systemic embolism;
diabetes mellitus; heart valve disease; vascular disease; liver
disease; thyroid disease; ischemic heart disease; nonischemic
dilated cardiomyopathy; renal disease; hemi- or paraplegia;
peptic ulcer; congenital anomalies of the heart; chronic
obstructive pulmonary disease; rheumatic disease; cancer;
prior shock or sepsis; arrhythmia; heart failure; alcohol abuse;
and hypertension), and concomitant pharmacotherapy includ-
ing nonsteroidal anti-inflammatory drugs, digoxin, corticos-
teroids, thyroid medication, statins, vitamin K antagonists,
antithrombotic medication, non–vitamin K antagonists, class
IC antiarrhythmic drugs, class III antiarrhythmic drugs, and
verapamil. Tables S1 and S2 specify comorbidities and
pharmacotherapy. Finally, we tested for interactions of death
and thromboembolic events with ischemic heart disease,
peripheral vascular disease, and diabetes mellitus. All model
assumptions were tested and found to be valid unless
otherwise indicated. A P value <0.05 was considered
statistically significant. All statistical analyses were performed
in SAS statistical software version 9.4 (SAS Institute) and
RStudio (Foundation for Open Access Statistics).
Premature Familial AF
As a selected sensitivity analysis, we restricted the group of
familial AF patients to those with a first-degree family member
diagnosed with AF before age 70 years. We matched those
patients with nonfamilial AF patients based on age at AF
diagnosis, year of AF diagnosis, and sex and compared the 2
groups regarding their risk of stroke and all-cause mortality.
Ethics
Approval from the Research Ethics Committee System is not
required for retrospective registry-based studies in Denmark.
The Danish Data Protection Agency approved use of the data
for this study (reference number: 2007-58-0015/GEH-2014-
013 I-Suite number: 02731).
Results
We identified a total of 232 172 AF patients diagnosed with
AF in Denmark in the period from 1995 to 2012. Of those
patients, 4332 had at least 1 AF proband. The cases were
matched with the same number of controls, leaving 3 familial
AF patients without a suitable match (Figure 1). Table 1
shows the baseline demographics and comorbidities of
patients with and without family history of AF. The median
age of familial and nonfamilial AF patients was 50 years
(interquartile range [IQR] 43–54 years). In the entire Danish
AF population diagnosed during 1995 to 2012, the median
age at AF diagnosis was 77 years (IQR 67–84 years). In the
entire AF population, 47% were women, whereas only 21.4%
of the familial AF patients were women. In general, the
matched nonfamilial AF patients had more comorbid illness,
including ischemic heart disease, vascular disease, diabetes
mellitus, alcohol abuse, peptic ulcer, and prior hospital
admission for shock and sepsis. For other comorbidities,
the 2 groups of patients were comparable. No significant
difference in CHA2DS2VASc scores existed between the 2
groups of patients (median CHA2DS2VASc score 0 [IQR 0–1]
for both patient groups, P=0.155).
Table 2 shows the use of pharmacotherapy at baseline.
Patients with nonfamilial AF received significantly more
treatment for comorbidities (including antiplatelets and
statins), whereas more patients with familial AF received
vitamin K antagonists and verapamil.
Outcomes
The median follow-up time from AF diagnosis was 3.4 years
(IQR 1.5–6.5 years) for familial AF patients and 3.3 years (IQR
3.3–6.4 years) for nonfamilial AF patients. After the first year
since AF diagnosis, 4.8% of the familial AF patients and 5.4%
of the nonfamilial AF patients were deceased. At 10 years
after the date of the AF diagnosis, 14.8% and 17.3% of the
familial and nonfamilial AF patients, respectively, were
deceased (Figure 2). In total, 1.6% of the patients with familial
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AF and 1.7% of the nonfamilial AF patients had a throm-
boembolic event during the first year after the AF diagnosis.
After 10 years of follow-up, 6.2% of the familial AF patients
and 5.8% of the nonfamilial AF patients had a thromboembolic
event. The median age at death was 53 years (IQR 47–57
years) for the familial AF group and 53 years (IQR 48–57
years) for the nonfamilial AF group. The analysis yielded a
higher survival probability in familial AF patients compared
with nonfamilial AF patients during follow-up (log-rank
P=0.01). Figure 3 illustrates the cumulative incidence of
thromboembolic events in patients with familial versus
nonfamilial AF. No differences were seen between the 2
groups (P=0.51). Figure 4 shows the incidence rates and
adjusted hazard ratios (HRs) of death and thromboembolism
among patients with family history of AF compared with those
without family history of AF. The crude HRs for death were
significantly lower in familial AF patients compared with
nonfamilial AF patients (HR 0.85, 95% CI 0.74–0.97), but after
adjustment for covariates, no differences were seen between
the familial and nonfamilial AF patients in terms of death (HR
0.91, 95% CI 0.79–1.04) and thromboembolism (HR 0.90,
95% CI 0.71–1.14). No interactions with ischemic heart
disease, vascular disease, and diabetes mellitus were found
for the main outcomes.
Premature Familial AF
Restricting the familial AF patient group to AF patients with a
first-degree family member diagnosed with AF before age
Table 1. Baseline Demographics and Comorbidities by
Family History of AF
Familial AF
(n=4329)
Nonfamilial
AF (n=4329) P Value
Demographics
Female, n (%) 927 (21.4) 927 (21.4) 1.000
Median age (IQR) 50 (43–54) 50 (43–54) 1.000
Comorbidities, n (%)
Alcohol abuse 84 (1.9) 116 (2.7) 0.026
Congenital anomaly
of the heart
131 (3.0) 147 (3.4) 0.361
COPD 170 (3.9) 189 (4.4) 0.332
Diabetes mellitus 164 (3.8) 218 (5.0) 0.006
Heart failure 691 (16.0) 692 (16.0) 1.000
Heart valve disease 25 (0.6) 32 (0.7) 0.426
Hypertension 1174 (27.1) 1129 (26.1) 0.285
Ischemic heart disease 689 (15.9) 761 (17.6) 0.041
Nonischemic dilated
cardiomyopathy
307 (7.1) 272 (6.3) 0.144
Peptic ulcer 243 (5.6) 296 (6.8) 0.021
Peripheral vascular disease 265 (6.1) 335 (7.7) 0.004
Prior shock or sepsis 187 (4.3) 272 (6.3) <0.001
Renal disease 153 (3.5) 180 (4.2) 0.146
Stroke, TIA, or systemic
thromboembolism
256 (5.9) 278 (6.4) 0.326
Thyroid disease 197 (4.6) 206 (4.8) 0.683
CHA2DS2-VASc*, n (%)
0 2599 (60.0) 2532 (58.5) 0.155
1 750 (17.3) 766 (17.7)
2 632 (14.6) 666 (15.4)
≥3 348 (8.0) 365 (8.4)
Median CHA2DS2-VASc*
(IQR)
0 (0–1) 0 (0–1)
Mean CHA2DS2-VASc*
(SD)
0.74 (1.09) 0.77 (1.11)
AF indicates atrial fibrillation; COPD, chronic obstructive pulmonary disease; IQR,
interquartile range; TIA, transient ischemic attack.
*Risk stratification scheme to assess stroke risk. CHA2DS2-VASc indicates congestive
heart failure or left ventricular dysfunction; hypertension; age ≥75 years; diabetes
mellitus; stroke, TIA, or systemic embolism; vascular disease; age 65–74 years; and sex
category (female).
Table 2. Use of Pharmacotherapy at Baseline, Including All
Dispensed Prescriptions From 3 Months Before the AF
Diagnosis Until 7 Days After Discharge
Medications, n (%)
Familial AF
(n=4329)
Nonfamilial
AF (n=4329) P Value
Adrenergic blockers 19 (0.4) 23 (0.5) 0.643
Antiplatelets* 616 (14.2) 700 (16.2) 0.013
Beta blockers 1654 (38.2) 1707 (39.4) 0.252
Calcium channel blockers 372 (8.6) 403 (9.3) 0.259
Class IC antiarrhythmic
agents†
99 (2.3) 82 (1.9) 0.229
Class III antiarrhythmic
agents‡
273 (6.3) 284 (6.6) 0.661
Digoxin 462 (10.7) 432 (10.0) 0.306
Diuretics 455 (10.5) 483 (11.2) 0.351
NOACs 125 (2.9) 120 (2.8) 0.796
NSAIDs 352 (8.1) 397 (9.2) 0.093
RAS inhibitors 764 (17.7) 785 (18.1) 0.575
Statins 405 (9.4) 505 (11.7) <0.001
Thyroid medication 100 (2.3) 105 (2.4) 0.778
Vasodilators 42 (1.0) 36 (0.8) 0.570
Verapamil 157 (3.6) 120 (2.8) 0.028
Vitamin K antagonists 1027 (23.7) 904 (20.9) 0.002
NOACs indicates non–vitamin K antagonist oral anticoagulation; NSAID, nonsteoridal
anti-inflammatory drugs; RAS, renin–angiotensin system.
*Includes adenosine diphosphate receptor antagonists and aspirin.
†Includes flecainide and propafenone.
‡Includes amiodarone, dronedarone, and sotalol.
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70 years resulted in a group of 2896 familial AF patients
matched with the same number of nonfamilial AF patients.
Figure 5 illustrates the incidence rates and crude and
adjusted HRs of death and thromboembolic events by family
history of AF. No differences were found between familial and
nonfamilial AF patients regarding risk of thromboembolic
events. Regarding all-cause mortality, the familial AF patients
had a significantly lower risk of death compared with the
nonfamilial AF patients (HR 0.83, 95% CI 0.69–0.99).
Discussion
This study examined a total of 8658 familial and nonfamilial
AF patients who were matched into 4329 clinically similar
pairs (same age at diagnosis, year of diagnosis, and sex). Our
study yielded 4 main findings. First, familial AF was diagnosed
at a young age. Second, 80% of patients with familial AF
were men. Third, patients with familial AF had less comorbid
illness than patients with nonfamilial AF. Fourth, after
adjustments for comorbidities and concomitant pharma-
cotherapy, long-term clinical outcomes were similar for
familial and nonfamilial AF patients.
Several studies have found the increased risk of AF in
those with a family member diagnosed with AF to be
dependent on the age of the family member at AF diagnosis;
low age at AF diagnosis increases the risk of family members
developing AF.10–12,16 In previous work from the Outcomes
Registry of Better Informed Treatment of Atrial Fibrillation
Figure 2. Kaplan–Meier curve for death by family history of atrial fibrillation (AF).
Figure 3. Cumulative incidence of thromboembolic events by family history of atrial fibrillation (AF).
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(ORBIT-AF), we compared familial and nonfamilial AF patients
and found familial AF patients to be significantly younger at
AF diagnosis than nonfamilial AF patients (median age
65 years [IQR 63–79 years] versus 70 years [IQR 61–77
years]).17 In this study, the age difference was even more
evident, with a median age at AF diagnosis for the familial AF
patients of 50 years (IQR 43–54 years) compared with the
nonfamilial AF patients, who had a median age at AF diagnosis
of 77 years (IQR 67–84 years). This finding supports the
hypothesis of a genetic predisposition to AF.
A study reporting the worldwide epidemiology of AF found
a higher proportion of men diagnosed with AF compared with
Figure 4. Incidence rates and adjusted hazard ratios (HRs) of long-term outcomes (death and thromboembolic complications) according to
family history of atrial fibrillation (AF). Covariates in the adjusted model: age at AF diagnosis, year of AF diagnosis, sex, comorbidities (including
dementia; AIDS; stroke, transient ischemic attack, or systemic embolism; diabetes mellitus; heart valve disease; vascular disease; liver disease;
thyroid disease; ischemic heart disease; renal disease; hemi- or paraplegia; peptic ulcer; congenital anomalies of the heart; chronic obstructive
lung disease; rheumatic disease; cancer; prior shock or sepsis; arrhythmia; heart failure; alcohol abuse; and hypertension), and concomitant
pharmacotherapy including nonsteroidal anti-inflammatory drugs, digoxin, corticosteroids, thyroid medication, statins, vitamin K antagonists,
antithrombotic medication, non–vitamin K antagonists, class IC antiarrhythmic drugs, class III antiarrhythmic drugs, and verapamil. *Per 1000
person-years.
Figure 5. For premature familial atrial fibrillation (AF), incidence rates and adjusted hazard ratios (HRs) of long-term outcomes (death and
thromboembolic complications) according to family history of atrial AF. Familial AF patients were defined as AF patients with a first-degree
family member diagnosed with AF before age 70 years. Covariates in the adjusted model: age at AF diagnosis, year of AF diagnosis, sex,
comorbidities (including dementia; aids; stroke, transient ischemic attack, or systemic embolism; diabetes mellitus; heart valve disease; vascular
disease; liver disease; thyroid disease; ischemic heart disease; renal disease; hemi- or paraplegia; peptic ulcer; congenital anomalies of the
heart; chronic obstructive lung disease; rheumatic disease; cancer; prior shock or sepsis; arrhythmia; heart failure; alcohol abuse; and
hypertension), and concomitant pharmacotherapy including nonsteroidal anti-inflammatory drugs, digoxin, corticosteroids, thyroid medication,
statins, vitamin K antagonists, antithrombotic medication, non–vitamin K antagonists, class IC antiarrhythmic drugs, class III antiarrhythmic
drugs, and verapamil. *Per 1000 person-years.
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women,25 and the Framingham Heart Study found male sex to
be an independent risk factor for developing AF.26 In this
study, only 21.4% of the patients were women, and in a study
by Øyen et al including all lone AF patients in Denmark aged
<60 years, 29.5% were women.12 In contrast, almost half of
the entire AF population in Denmark is composed of women
(47%). The increasing population of especially elderly women
may explain this sex difference across ages.
In the study from ORBIT-AF, we found familial AF patients
to have less comorbid illness than nonfamilial AF patients,
including chronic obstructive pulmonary disease and coro-
nary artery disease. Despite this, no differences existed in
median CHA2DS2-VASc scores between the 2 patient
groups.17 This finding is partly in accordance with our
results in this report, in which we found lower prevalence of
ischemic heart disease and several other comorbidities in
patients with familial AF, whereas the 2 patient groups were
comparable in terms of CHA2DS2-VASc score. In the ORBIT-
AF study, the familial AF patients had less comorbidity but
more symptoms than nonfamilial AF patients, and this result
was independent of age. In this current study, it was not
possible to compare symptom burden in the 2 patient
groups.
We followed familial and nonfamilial AF patients for long-
term follow-up and found that patients with familial AF had
significantly lower crude risk of all-cause mortality compared
with nonfamilial AF patients. The 2 patient groups were
comparable regarding crude long-term risk of thromboembolic
events. The crude increased risk of death for nonfamilial AF
patients was expected because of the increased comorbidity
in nonfamilial AF patients, and after multivariable risk
adjustment, the difference was not statistically significant.
The differences in risk of thromboembolic events in familial
and nonfamilial patients remained insignificant after multi-
variable adjustment. Despite statistical nonsignificance, we
cannot fully exclude the possibility of a difference in
thromboembolic risk between familial and nonfamilial AF
patients. In a selected sensitivity analysis, we restricted the
group of familial AF patients to those with a first-degree family
member diagnosed with AF before age 70 years. This did not
change the results remarkably, but the risk of death became
significantly lower among familial AF patients compared with
nonfamilial AF patients, even in the adjusted analysis.
The recent acknowledgement of a familial form of AF
should lead to considerations about the clinical course of
familial AF and whether familial AF patients would benefit
from another treatment strategy than the general AF popu-
lation. We previously found that familial AF patients had more
symptoms than nonfamilial AF patients.17 In this study, the
focus was on death and thromboembolic complications. We
found no differences in the long-term risk of thromboembolic
complications between familial and nonfamilial AF patients,
but a trend was noted toward lower risk of death for familial
AF patients compared with nonfamilial AF patients. Conse-
quently, our results do not suggest different antithrombotic
treatment approaches for familial AF patients and the general
AF population.
In 2013, Christophersen et al reported a higher rate of
death among AF patients with a twin diagnosed with AF
compared with AF patients with a twin without AF.27 In our
previous work from ORBIT-AF, we found no differences in risk
of death and thromboembolic complications in patients with
and without familial AF. The present study is, to our
knowledge, the first to examine the risk of death and
thromboembolic complications during long-term follow up,
and more studies are needed to further confirm these results.
In addition, this study did not focus on specific genetic
mutations associated with AF, and studies of genetic
subgroups of familial AF and their long-term risk of compli-
cations are warranted.
This study has several limitations. First, we did not have
relevant demographic variables such as blood pressure, body
mass index, and race. In addition, no data about specific
families, lifestyle factors, and familial hypertension were
available. We also were not able to differentiate between
paroxysmal, persistent, and permanent AF. The study was a
retrospective registry study that did not allow for any
causation to be drawn but rather only associations. In
contrast, the Danish registries include complete and nation-
wide data and hold a unique and unselected sample of
persons with complete information and many years of follow-
up. Second, the registries included complete family informa-
tion only from 1942 onward. This may have resulted in
underestimation of patients with familial AF. Third, we ended
up excluding the majority of the control group by excluding
those without complete information about both parents. This
was done to ensure that the controls did not have an
unknown parent diagnosed with AF. Because the familial AF
population was very young and because the complete
registration of both parents improved over time, the remaining
controls were young, and thus it was possible to do an almost
complete 1:1 match of cases and controls without compro-
mising the matching criteria. Fourth, the Danish National
Patient Registry included only data from hospital contacts,
and it is possible that some patients were diagnosed and
treated by general practitioners. This may have caused some
degree of selection bias, albeit minimal.
In conclusion, in a nationwide cohort, we found that
familial AF was diagnosed at a younger age and more often in
men compared with nonfamilial AF patients. Patients with
familial AF had less comorbid illness than nonfamilial AF
patients matched for age, year of diagnosis, and sex but did
not differ significantly in their long-term adjusted risks of all-
cause mortality and thromboembolic complications.
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Table S1. Specification of comorbidities by International Classification 
of Diseases (ICD),  ICD-8 and ICD-10 codes
Comorbidity ICD-8 and ICD-10 codes 
Aids ICD-8: 042-044 
ICD-10: DB20-DB24 
Alcohol abuse ICD-8: 291, 303, 5710 
ICD-10: DG312, DG621, DG721, DE24.4, 
DE52, DF10, DI426, DK292, DK70, DK860, 
DL278A, DO354, DZ714, DZ721 
Arrhythmia ICD-8: 4273-4275, 4276, 4279 
ICD-10: DI46-DI49 
Dementia ICD-8: 290 
ICD-10: DG30, DG311, DG312 
Cancer ICD-8: 140-195, 196-199, 200-209 
ICD-10: DC00-DC97 
Congenital anomaly of the heart ICD-8: 74600-74799, 75900, 75901, 75909 
ICD-10: DQ200-DQ289 
Chronic Obstructive Pulmonary Disease ICD-8: 490-492 
ICD-10: DJ42, DJ44 
Diabetes ATC: A10 (3 months before to 7 days after 
the AF diagnosis) 
Heart failure ICD-8:  425, 4270, 4271 
ICD-10: DI110, DI42, DI50, DJ819 
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Heart valve disease ICD-8: 39500-39502, 39508, 39509, 39600-
39604, 39608, 39609 
ICD-10: DI05, DI06, DZ952, DZ954, 
DI080A, DI081A, DI082A, DI083A, KFKD, 
KFKH, KFMD, KFMH, KFGE, KFJF 
Hemi- or paraplegia ICD-8: 342, 344 
ICD-10: DG041, DG81, DG82, DT144 
Ischemic heart disease ICD-8: 410-414  
ICD-10: DI20-DI25 
Liver disease ICD-8: 456, 571, 572 
ICD-10: DB150, DB160, DB190, DK70-
DK77  
Peptic ulcer ICD-8: 531-534 
ICD-10: DK221, DK25-27, K29 
Renal disease ICD-8: 582-586, 588 
ICD-10: DI12, DI13, DN03, DN04, DN17-
DN19, DR34, DT858, DT859, DZ992 
Rheumatic disease ICD-8: 7100, 7101, 7104, 7140-7142, 7148, 
725 
ICD-10: DM05, DM06, DM32-DM34, 
DM353 
Shock or sepsis ICD-8: 038, 7829 
ICD-10: DA41, DR57 
Stroke/TIA/systemic embolism ICD-8: 433-435, 43601, 43690, 444 
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ICD-10: DG458, DG459, DI63, DI64, DI74 
Thyroid disease ICD-8: 240-246 
ICD-10: DE07 
Vascular disease ICD-8: 410, 440 
ICD-10: DI21, DI70 
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Table S2. Specification of concomitant pharmacotherapy by  Anatomical 
Therapeutic Chemical Classification (ATC)-codes (3 month before to 7 days 
after the AF diagnosis) 
Pharmacotherapy ACT-codes 
Adrenergic blockers C02A, C02B, C02C 
Anti-thrombotic medication B01AC04, B01AC06, B01AC22, B01AC22, 
B01AC24, N02BA01,  
Beta blockers C07A, C07B, C07C, C07D, C07F 
Calcium channel blockers C08, C07F, C09BB, C09DB 
Class IC antiarrhythmic agents* C01BC 
Class III antiarrhythmic agents† C01BD, C07AA 
Corticosteroids H02AB 
Digoxin C01A 
Diuretics C02DA, C02L, C03A, C03B, C03D, C03E, 
C03X, C07C, C07D, C08G, C09BA, 
C09DA, C09XA52 
NOACs‡ B01AF01, B01AF02, B01AE07 
NSAID§ M01A 
RAS-inhibitors| C09AA, C09BA, C09BB, C09CA, C09DA, 
C09DB, C09XA02, C09XA52 
Statins C10AA 
Thyroid medication H03 
Vasodilators C02DB, C02DD, C02DG, C04, C05 
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Verapamil C08DA 
Vitamin K antagonists B01AA03, B01AA04 
*Includes flecainide and propafenone
†Includes amiodarone, dronedarone, and sotalol
‡Non-vitamin K antagonist oral anticoagulants
§Nonsteoridal anti-inflammatory drugs
|Includes angiotensin-2-inhibitors and ACE-inhibitors 
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